Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What CAGR Is Anticipated for the Inactivated Vaccines Market Through 2029?

The size of the inactivated vaccines market has been experiencing consistent growth over the past few years. The market, which was valued at $6.19 billion in 2024, is projected to increase to $6.37 billion in 2025, with a compound annual growth rate (CAGR) of 2.8%. This historical growth trend is linked to efforts to eradicate polio, the implementation of influenza immunisation programs, the emergence of new infectious diseases, and regulatory approvals.

The market size of inactivated vaccines is projected to experience consistent expansion in the upcoming years. It is set to reach “$7.58 billion by the year 2029, growing at a compound annual growth rate (CAGR) of 4.5%.” This growth during the forecast period can be associated with readiness for pandemics, wider vaccine coverage, advancements in biomanufacturing, and initiatives toward health equity. Key trends for this forecast period encompass mRNA vaccine platforms, combined vaccines, heat-stable vaccines, and digital vaccine passports.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13018&type=smp

What Market Forces Are Driving The Inactivated Vaccines Sector In 2025 And Beyond?

The escalating occurrence of contagious diseases is forecasted to drive an expansion in the inactivated vaccine market. Contagious diseases, which are viruses, bacteria, parasites, or fungi-based illnesses that can be transmitted between individuals, produce a variety of symptoms and health issues. Tuberculosis is a prime example of such diseases. Inactivated vaccines, which use non-living pathogens to trigger an immune response, are highly effective in preventing diseases such as polio, hepatitis A, and influenza. In November 2023, the Centers for Disease Control and Prevention, a key national public health organization in the USA, published an article stating that the count of tuberculosis patients in the USA soared from 8,320 in 2022 to 9,615 in 2023, marking an increase of 1,295 cases. As such, the escalating occurrence of contagious diseases is fueling expansion in the inactivated vaccine market.

The inactivated vaccines market covered in this report is segmented –

1) By Type: Viral Vaccine, Bacterial Vaccine

2) By Method Of Inactivation: Solvent Detergent, Radiation, pH Concentration, Heat Inactivation, Other Methods Of Inactivation

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels

Subsegments:

1) By Viral Vaccine: Inactivated Poliovirus Vaccine (IPV), Inactivated Influenza Vaccine, Inactivated Hepatitis A Vaccine, Inactivated Rabies Vaccine

2) By Bacterial Vaccine: Inactivated Typhoid Vaccine, Inactivated Cholera Vaccine, Inactivated Pertussis Vaccine, Inactivated Plague Vaccine

Which Trends Are Redefining The Future Landscape Of The Inactivated Vaccines Industry?

Leading firms in the inactivated vaccines sector are introducing sophisticated and novel inactivated vaccines to maintain their market standing. An inactivated vaccine comprises inactivated pathogens including viruses, bacteria, or other microbes that have been cultured and subsequently killed to eliminate their disease-causing abilities. For example, in January 2022, GSK PLC, a pharmaceutical and biotechnology firm based in the UK, launched a fresh inactivated vaccine called Shingrix to help thwart shingles (Herpes zoster). Shingrix is a non-live, adjuvanted recombinant subunit vaccine given intramuscularly in two doses. Initially, the vaccine was indicated for people aged 50 and up, but its use has recently been extended to cover those aged 18 and up who have a higher risk of getting shingles due to immune deficiency or suppression resulting from a confirmed disease or therapy.

Which Firms Are Considered Leaders In The Inactivated Vaccines Market Space?

Major companies operating in the inactivated vaccines market are Pfizer Inc., Johnson & Johnson Services Inc., Sinopharm Group Co. Ltd., Merck & Co. Inc., Sanofi S.A., GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., CSL Limited, Daiichi Sankyo Company Limited, Mitsubishi Tanabe Pharma Corporation, Novavax Inc., Zydus Lifesciences Ltd., Sinovac Biotech Ltd., Biological E Limited, Hualan Biological Engineering Inc., CanSino Biologics Inc., Shenzhen Kangtai Biological Products Co. Ltd., Serum Institute of India Pvt. Ltd., Beijing Tiatan Biological Products Co. Ltd., Valneva SE, Bavarian Nordic A/S., Beijing Minhai Biotechnology Co. Ltd., Bharat Biotech International Limited, Panacea Biotec Ltd., Sinergium Biotech SA, Bharat Immunologicals and Biologicals Corporation Limited, Haffkine Biopharmaceutical Corporation Limited, Incepta Vaccine Ltd., Changchun BCHT Biotechnology Co. Ltd., .

https://www.thebusinessresearchcompany.com/report/inactivated-vaccines-global-market-report

What Role Do Regional Policies And Investments Play In Inactivated Vaccines Market Expansion?

North America was the largest region in the inactivated vaccines market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in inactivated vaccines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=13018&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model